Natera (NASDAQ:NTRA) Downgraded by BidaskClub

BidaskClub lowered shares of Natera (NASDAQ:NTRA) from a strong-buy rating to a buy rating in a research note published on Saturday, BidAskClub reports.

A number of other research analysts also recently commented on the stock. ValuEngine upgraded shares of Natera from a hold rating to a buy rating in a research note on Friday, November 1st. Canaccord Genuity reissued a buy rating and set a $44.00 price objective on shares of Natera in a report on Wednesday, October 16th. Craig Hallum boosted their target price on shares of Natera from $37.00 to $49.00 and gave the stock a buy rating in a research report on Thursday, November 7th. Piper Jaffray Companies set a $45.00 target price on shares of Natera and gave the company a buy rating in a research note on Friday, October 11th. Finally, Cowen increased their price target on shares of Natera from $30.00 to $42.00 and gave the stock an average rating in a research report on Friday, October 18th. Four analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Natera presently has a consensus rating of Buy and a consensus target price of $42.50.

Shares of NTRA opened at $34.12 on Friday. The firm has a market cap of $2.65 billion, a price-to-earnings ratio of -15.87 and a beta of 1.40. The company has a quick ratio of 2.26, a current ratio of 2.35 and a debt-to-equity ratio of 1.20. The business’s 50 day moving average is $38.20 and its two-hundred day moving average is $30.87. Natera has a 52-week low of $11.08 and a 52-week high of $40.92.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Wednesday, November 6th. The medical research company reported ($0.33) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.20. The business had revenue of $77.90 million during the quarter, compared to the consensus estimate of $73.97 million. Natera had a negative net margin of 42.45% and a negative return on equity of 252.79%. The business’s quarterly revenue was up 19.3% compared to the same quarter last year. During the same quarter last year, the company earned ($0.49) earnings per share. On average, equities analysts expect that Natera will post -2.15 earnings per share for the current fiscal year.

In other news, CTO Jonathan Sheena sold 1,033 shares of the business’s stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $29.50, for a total transaction of $30,473.50. Following the completion of the transaction, the chief technology officer now owns 241,937 shares of the company’s stock, valued at $7,137,141.50. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Michael Burkes Brophy sold 15,701 shares of the company’s stock in a transaction dated Monday, October 21st. The stock was sold at an average price of $40.00, for a total transaction of $628,040.00. Following the transaction, the chief financial officer now owns 16,005 shares of the company’s stock, valued at approximately $640,200. The disclosure for this sale can be found here. Insiders have sold a total of 63,854 shares of company stock worth $2,231,769 over the last quarter. Insiders own 9.29% of the company’s stock.

Large investors have recently modified their holdings of the stock. Vanguard Group Inc. boosted its stake in Natera by 17.4% during the 2nd quarter. Vanguard Group Inc. now owns 5,604,296 shares of the medical research company’s stock valued at $154,567,000 after purchasing an additional 832,187 shares during the period. BlackRock Inc. grew its holdings in Natera by 74.4% in the 2nd quarter. BlackRock Inc. now owns 4,842,318 shares of the medical research company’s stock worth $133,552,000 after buying an additional 2,065,977 shares in the last quarter. Jennison Associates LLC grew its holdings in Natera by 24.4% in the 2nd quarter. Jennison Associates LLC now owns 4,434,727 shares of the medical research company’s stock worth $122,310,000 after buying an additional 869,420 shares in the last quarter. Orbimed Advisors LLC grew its holdings in Natera by 199.2% in the 2nd quarter. Orbimed Advisors LLC now owns 3,224,328 shares of the medical research company’s stock worth $88,927,000 after buying an additional 2,146,742 shares in the last quarter. Finally, Macquarie Group Ltd. increased its position in Natera by 1.7% in the 2nd quarter. Macquarie Group Ltd. now owns 2,262,808 shares of the medical research company’s stock valued at $62,408,000 after acquiring an additional 36,939 shares during the period. Hedge funds and other institutional investors own 84.90% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

See Also: Treasury Bonds

Analyst Recommendations for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.